Home>>Signaling Pathways>> Others>> MAGL>>JZP-430

JZP-430 Sale

目录号 : GC34640

An ABHD6 inhibitor

JZP-430 Chemical Structure

Cas No.:1672691-74-5

规格 价格 库存 购买数量
5mg
¥2,520.00
现货

电话:400-920-5774 Email: sales@glpbio.cn

Customer Reviews

Based on customer reviews.

Sample solution is provided at 25 µL, 10mM.

产品文档

Quality Control & SDS

View current batch:

产品描述

JZP 430 is an inhibitor of α/β-hydrolase domain-containing protein 6 (ABHD6; IC50 = 0.044 for the human enzyme).1 It is selective for ABHD6 over fatty acid amid hydrolase (FAAH) and monoacylglycerol lipase (MAGL) when used at a concentration of 2.5 ?M, ABHD12 at 1 ?M, as well as lysosomal acid lipase (LAL) and cannabinoid 1 (CB1) and CB2 receptors at 10 ?M.

1.Patel, J.Z., Nevalainen, T.J., Savinainen, J.R., et al.Optimization of 1,2,5-thiadiazole carbamates as potent and selective ABHD6 inhibitorsChemMedChem10(2)253-265(2015)

Chemical Properties

Cas No. 1672691-74-5 SDF
Canonical SMILES O=C(OC1=NSN=C1N2CCOCC2)N(C3CCCCCCC3)C
分子式 C16H26N4O3S 分子量 354.47
溶解度 DMSO : 100 mg/mL (282.11 mM; Need ultrasonic) 储存条件 Store at -20°C
General tips 请根据产品在不同溶剂中的溶解度选择合适的溶剂配制储备液;一旦配成溶液,请分装保存,避免反复冻融造成的产品失效。
储备液的保存方式和期限:-80°C 储存时,请在 6 个月内使用,-20°C 储存时,请在 1 个月内使用。
为了提高溶解度,请将管子加热至37℃,然后在超声波浴中震荡一段时间。
Shipping Condition 评估样品解决方案:配备蓝冰进行发货。所有其他可用尺寸:配备RT,或根据请求配备蓝冰。

溶解性数据

制备储备液
1 mg 5 mg 10 mg
1 mM 2.8211 mL 14.1056 mL 28.2111 mL
5 mM 0.5642 mL 2.8211 mL 5.6422 mL
10 mM 0.2821 mL 1.4106 mL 2.8211 mL
  • 摩尔浓度计算器

  • 稀释计算器

  • 分子量计算器

质量
=
浓度
x
体积
x
分子量
 
 
 
*在配置溶液时,请务必参考产品标签上、MSDS / COA(可在Glpbio的产品页面获得)批次特异的分子量使用本工具。

计算

动物体内配方计算器 (澄清溶液)

第一步:请输入基本实验信息(考虑到实验过程中的损耗,建议多配一只动物的药量)
给药剂量 mg/kg 动物平均体重 g 每只动物给药体积 ul 动物数量
第二步:请输入动物体内配方组成(配方适用于不溶于水的药物;不同批次药物配方比例不同,请联系GLPBIO为您提供正确的澄清溶液配方)
% DMSO % % Tween 80 % saline
计算重置

Research Update

Optimization of 1,2,5-thiadiazole carbamates as potent and selective ABHD6 inhibitors

ChemMedChem 2015 Feb;10(2):253-65.PMID:25504894DOI:PMC4471478

At present, inhibitors of α/β-hydrolase domain 6 (ABHD6) are viewed as a promising approach to treat inflammation and metabolic disorders. This article describes the development of 1,2,5-thiadiazole carbamates as ABHD6 inhibitors. Altogether, 34 compounds were synthesized, and their inhibitory activity was tested using lysates of HEK293 cells transiently expressing human ABHD6 (hABHD6). Among the compound series, 4-morpholino-1,2,5-thiadiazol-3-yl cyclooctyl(methyl)carbamate (JZP-430) potently and irreversibly inhibited hABHD6 (IC50 =44 nM) and showed ∼230-fold selectivity over fatty acid amide hydrolase (FAAH) and lysosomal acid lipase (LAL), the main off-targets of related compounds. Additionally, activity-based protein profiling indicated that JZP-430 displays good selectivity among the serine hydrolases of the mouse brain membrane proteome. JZP-430 has been identified as a highly selective, irreversible inhibitor of hABHD6, which may provide a novel approach in the treatment of obesity and type II diabetes.